trpm7

Fingolimod hydrochloride (FTY720) , a novel immune modulator, is a sphingosine 1-phosphate (S1P) antagonist (IC50: 0.033 nM in K562 and NK cells).

TRPM7-IN-1 (compound SUD) is a benzamide-urea derivative and an effective inhibitor of TRPM7. This compound induces cell cycle arrest and apoptosis in MCF-7 and BGC-823 cells, reducing their migration capabilities. It decreases vimentin expression while increasing E-cadherin expression. TRPM7-IN-1 reduces TRPM7-like currents and inhibits TRPM7 expression by activating the PI3K Akt signaling pathway. This compound shows potential as a therapeutic agent for reducing breast and gastric cancer metastasis by targeting TRPM7 expression and activity.

AAL-149, an analog of FTY720 and a TRPM7 inhibitor (IC50 = 1.081 μM), exhibits multiple anti-inflammatory effects without targeting S1P receptors. It is applicable in anti-inflammatory research.

Mesendogen is an inhibitor of TRPM6. Mesendogen alters magnesium homeostasis, promotes mesoderm and definitive endoderm differentiation.

Xeniafaraunol A (compound 31) is a potent inhibitor of the transient receptor potential melastatin 7 (TRPM7) channel [1].

VPC01091.4 (VPC4) is a TRPM7 inhibitor that blocks TRPM7 current at low micromolar concentrations and serves as an efficacious anti-inflammatory agent, arresting systemic inflammation in vivo [1].

BTB 06061 is a TRPM7 inhibitor utilized in the study of ischemic diseases.